Literature DB >> 21505216

Strength of TCR-peptide/MHC interactions and in vivo T cell responses.

Emily Corse1, Rachel A Gottschalk, James P Allison.   

Abstract

The TCR can detect subtle differences in the strength of interaction with peptide/MHC ligand and transmit this information to influence downstream events in T cell responses. Manipulation of the factor commonly referred to as TCR signal strength can be achieved by changing the amount or quality of peptide/MHC ligand. Recent work has enhanced our understanding of the many variables that contribute to the apparent cumulative strength of TCR stimulation during immunogenic and tolerogenic T cell responses. In this review, we consider data from in vitro studies in the context of in vivo immune responses and discuss in vivo consequences of manipulation of strength of TCR stimulation, including influences on T cell-APC interactions, the magnitude and quality of the T cell response, and the types of fate decisions made by peripheral T cells.

Mesh:

Substances:

Year:  2011        PMID: 21505216     DOI: 10.4049/jimmunol.1003650

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  94 in total

1.  EGFR inhibitors, MHC expression and immune responses : Can EGFR inhibitors be used as immune response modifiers?

Authors:  Brian P Pollack
Journal:  Oncoimmunology       Date:  2012-01-01       Impact factor: 8.110

2.  Low-Affinity Memory CD8+ T Cells Mediate Robust Heterologous Immunity.

Authors:  Scott M Krummey; Ryan J Martinez; Rakieb Andargachew; Danya Liu; Maylene Wagener; Jacob E Kohlmeier; Brian D Evavold; Christian P Larsen; Mandy L Ford
Journal:  J Immunol       Date:  2016-02-10       Impact factor: 5.422

3.  Vaccination with High-Affinity Epitopes Impairs Antitumor Efficacy by Increasing PD-1 Expression on CD8+ T Cells.

Authors:  Christopher D Zahm; Viswa T Colluru; Douglas G McNeel
Journal:  Cancer Immunol Res       Date:  2017-06-20       Impact factor: 11.151

4.  Wide-scale quantitative phosphoproteomic analysis reveals that cold treatment of T cells closely mimics soluble antibody stimulation.

Authors:  Qinqin Ji; Arthur R Salomon
Journal:  J Proteome Res       Date:  2015-04-03       Impact factor: 4.466

Review 5.  T cells in the control of organ-specific autoimmunity.

Authors:  Jeffrey A Bluestone; Hélène Bour-Jordan; Mickie Cheng; Mark Anderson
Journal:  J Clin Invest       Date:  2015-05-18       Impact factor: 14.808

6.  Cell-surface MHC density profiling reveals instability of autoimmunity-associated HLA.

Authors:  Hiroko Miyadera; Jun Ohashi; Åke Lernmark; Toshio Kitamura; Katsushi Tokunaga
Journal:  J Clin Invest       Date:  2014-12-08       Impact factor: 14.808

7.  Thymic expression of a T-cell receptor targeting a tumor-associated antigen coexpressed in the thymus induces T-ALL.

Authors:  Yongzhi Cui; Masahiro Onozawa; Haven R Garber; Leigh Samsel; Ziyao Wang; J Philip McCoy; Sandra Burkett; Xiaolin Wu; Peter D Aplan; Crystal L Mackall
Journal:  Blood       Date:  2015-03-26       Impact factor: 22.113

8.  Mapping the stochastic sequence of individual ligand-receptor binding events to cellular activation: T cells act on the rare events.

Authors:  Jenny J Y Lin; Shalini T Low-Nam; Katherine N Alfieri; Darren B McAffee; Nicole C Fay; Jay T Groves
Journal:  Sci Signal       Date:  2019-01-15       Impact factor: 8.192

9.  Cutting edge: CD4 T cells reactive to an islet amyloid polypeptide peptide accumulate in the pancreas and contribute to disease pathogenesis in nonobese diabetic mice.

Authors:  Rocky L Baker; Thomas Delong; Gene Barbour; Brenda Bradley; Maki Nakayama; Kathryn Haskins
Journal:  J Immunol       Date:  2013-09-16       Impact factor: 5.422

10.  The Antitumor Effects of Vaccine-Activated CD8+ T Cells Associate with Weak TCR Signaling and Induction of Stem-Like Memory T Cells.

Authors:  Sha Wu; Wei Zhu; Yibing Peng; Lan Wang; Yuan Hong; Lei Huang; Dayong Dong; Junping Xie; Todd Merchen; Edward Kruse; Zong Sheng Guo; David Bartlett; Ning Fu; Yukai He
Journal:  Cancer Immunol Res       Date:  2017-08-29       Impact factor: 11.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.